Overview

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Status:
Completed
Trial end date:
2014-02-25
Target enrollment:
Participant gender:
Summary
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aclaris Therapeutics, Inc.